Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
BTG plc Close Period Update
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.
Daclizumab Therapy for Multiple Sclerosis.
Pregnancy outcomes in patients exposed to interferon beta-1b.
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
Impact of sleep disorder treatment on fatigue in multiple sclerosis.
Toxicity of Teriflunomide in Aryl Hydrocarbon Receptor Deficient Mice.
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis.
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
TGN1412: From Discovery to Disaster.
Genzyme’s Lemtrada Approved by the FDA
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
Value and Efficacy of Transcranial Direct Current Stimulation in the Cognitive Rehabilitation: A Critical Review Since 2000.
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
Fatal Acute Myeloid Leukemia With 11q23 MLL Gene Rearrangement Following Mitoxantrone Treatment in a Case of Childhood-onset Multiple Sclerosis.
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
More to come: humoral immune responses in MS.
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)

Pages